Inhibin a as a tumor marker for primary bilateral macronodular adrenal hyperplasia

5Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

Primary bilateral macronodular adrenal hyperplasia (PBMAH) is a rare cause of ACTH-independent Cushing syndrome (CS). This condition is characterized by glucocorticoid and/or mineralocorticoid excess, and is commonly regulated by aberrant G-protein coupled receptor expression may be subclinical, allowing the disease to progress for years undetected. Inhibin A is a glycoprotein hormone and tumor marker produced by certain endocrine glands including the adrenal cortex, which has not been previously investigated as a potential tumor marker for PBMAH. In the present report, serum inhibin A levels were evaluated in three patients with PBMAH before and after adrenalectomy. In all cases, serum inhibin A was elevated preoperatively and subsequently fell within the normal range after adrenalectomy. Additionally, adrenal tissues stained positive for inhibin A. We conclude that serum inhibin A levels may be a potential tumor marker for PBMAH.

Cite

CITATION STYLE

APA

Wurth, R., Kamilaris, C., Nilubol, N., Sadowski, S. M., Berthon, A., Quezado, M. M., … Hannah-Shmouni, F. (2020). Inhibin a as a tumor marker for primary bilateral macronodular adrenal hyperplasia. Endocrinology, Diabetes and Metabolism Case Reports, 2020(1), 1–6. https://doi.org/10.1530/EDM-20-0006

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free